PDCD1 and metastatic melanoma: Nevertheless, immune checkpoint inhibitor therapy has revolutionized the treatment for both locally advanced and metastatic melanoma by targeting the cytotoxic T-lymphocyte antigen 4 (CTLA-4) and the programmed cell death 1 (PD1) proteins [6,13].